Platelet Surface Activation Markers after DDAVP Infusion in Healthy Subjects^[*]

• 

The study was supported in part by a grant from the Swiss National Science Foundation (No. 32-36575.92)

• References

• 1 Editorial: Desmopressin and arterial thrombosis. Lancet 1989; 1: 938-939
• 2 Mannucci PM, Lusher JM. Desmopressin and Thrombosis. Lancet 1989; 2: 675-676
• 3 Cattaneo M, Lombardi R, Bettega D, Lecchi A, Mannucci PM. Shear induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscl Thromb 1993; 13: 393-397
• 4 Andersson TL, Solem JO, Tengborn L, Vinge E. Effects of desmopressin acetate on platelet aggregation, von Willebrand factor and blood loss after cardiac surgery with extracorporeal circulation. Circulation 1990; 81: 872-878
• 5 D’Angelo A, Capitanio A, Smith JB, Valsecchi C, Mannucci PM. Effects of des-amino-D-arginine vasopressin (DDAVP) on plasma levels of platelet and endothelial cell release products. Thromb Haemost 1983; 49: 64
• 6 Abrams CS, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost 1991; 65: 467-473
• 7 Sloand EM, Alyono D, Klein HG, Chang P, Yu M, Lightfoot FG, Kessler C. l-desamino-8-D-arginine vasopressin (DDAVP) increases platelet expression of glycoprotein lb in patients with disorders of platelet function. Am J Hematol 1994; 46: 199-207